Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.

Published in:

Infectious Diseases & Therapy, 2023, v. 12, n. 9, p. 2269, doi. 10.1007/s40121-023-00861-7

By:

• Hobbs, F. D. Richard;
• Montgomery, Hugh;
• Padilla, Francisco;
• Simón-Campos, Jesus Abraham;
• Kim, Kenneth;
• Arbetter, Douglas;
• Padilla, Kelly W.;
• Reddy, Venkatesh Pilla;
• Seegobin, Seth;
• Streicher, Katie;
• Templeton, Alison;
• Viani, Rolando M.;
• Johnsson, Eva;
• Koh, Gavin C. K. W.;
• Esser, Mark T.

Publication type:

Article